Biotech & Longevity
Where it stands
As of 3 August 2026
Money keeps pouring in while trial results and FDA panels face harder questions, and resistant infections keep gaining ground.
Forces in tension
GSK-Relation, J&J's $785M Sail option, and AZ-BMS merger talks in one week
a full week on medicine losing its footrace with resistant bugs
split verdicts, peptides backed over the agency's own scientists
clean trials that still miss what matters; a passing drug whose stock fell 60%
blood-based cancer screening advancing, with debate over what it proves
the ZEUS phase 3 miss dents the idea that lowering hsCRP protects the heart
What to watch
Whether ziltivekimab's two remaining heart trials, due in 2027, and the next split FDA votes ease or deepen the doubt over how drug results are judged.
This board is the synthesized picture of 9 recent Biotech & Longevity editions. It describes where things stand — the forces, not a forecast, and never advice on what to do.